简介：AIM:Todescribetheinvolutionpatternsofvesselgrowthofretinathroughfluoresceinangiography(FA)ofchildren,whohadbeenundertreatmentupto1ypreviouslyintravitrealranibizumab(IVR)asmonotherapyforretinopathyofprematurity(ROP).METHODS:Thisisaretrospectivestudy.ThemedicalinformationandFAof17children(34eyes)whoseareaofavascularretinafromtheoraserratawasmorethantwodiscdiameters(DD)wereanalyzed.RESULTS:Among34eyes,allwerethepresenceoffinger-shapedvesselsandarteriolar-venularshunts(100%,34/34eyes).Popcornabnormalitieswerefoundinmostoftheeyes(94.1%,32/34eyes).Furthermore,inmanycases(23.5%,8/34eyes),therewereleakagepersistingintheregionofthejunctionbetweenavascularandvascularretina.Incontrast,just2eyes(5.9%)showeddamageofretinalcapillarybedand3eyes(8.8%)showedlargeareaofretinalpigmentepithelium(RPE)atrophy.CONCLUSION:AlthoughIVRcanbeveryeffectiveinROP,weshouldremaincautiousasinfantsmayremainavascularperipheralretinasandabnormalvessel.FAallowsaccuratevisualizationofvesselabnormalitiesineyeswithROP,whichwillbehelpfultoaffectassessmentofdiseaseactivityandtherapeuticeffect.

简介：AIM:Tocomparetheeffectivenessandsafetybetweenbevacizumabandranibizumabinthetreatmentofagerelatedmaculardegeneration(AMD)throughasystematicreviewandmeta-analysis.METHODS:Weperformedacomprehensivesearchofrandomizedcontrolledtrials(RCTs),non-RCTs,casecontrolandcohortstudiesthatcomparedbevacizumabandranibizumabusingPubMedandtheCochraneLibrary.Aftertherelateddatawereextractedbytwoinvestigatorsindependently,pooledweightedmeandifferences(WMDs)andriskratios(RRs)with95%confidenceintervals(CIs)wereestimatedusingarandom-effectsorafixed-effectsmodel.RESULTS:AtotaloffourRCTsinvolving1927patientsandelevenretrospectivecaseseriesinvolving2296patientswereincluded.Fortheprimaryoutcomes,nosignificantdifferenceswerefoundbetweenranibizumabgroupandbevacizumabgroupinvisualacuity(WMD:-0.04;95%CI:-0.08to0.00;P=0.06),bestcorrectedvisualacuity(WMD:-0.05;95%CI:-0.10to0.00;P=0.05),retinathickness(WMD:-4.69;95%CI:-13.15to3.76;P=0.86)andfovealthickness(WMD:10.91;95%CI:-14.73to36.56;P=0.40).Thepooledanalysesintheevaluationofsafetyshowedthatcomparedtobevacizumab,ranibizumabwasassociatedwithdecreasedrisksofocularinflammation(RR:0.45;95%CI:0.23to0.89;P=0.02)andvenousthromboticevents(RR:0.27;95%CI:0.08to0.89;P=0.03).However,therewerenosignificantdifferencesobservedindeaths(P=0.69)andarterialthromboembolicevents(P=0.71)betweenthetwogroups.CONCLUSION:Withequalclinicalefficacy,ranibizumabwasfoundtobeassociatedwithlessadverseeventscomparedtobevacizumab,indicatingthatranibizumabmightbeasafermanagement.

简介：AIMTo调查经历了intravitrealranibizumabmonotherapy对待neovascular的病人的长期的视觉、解剖的结果年龄相关的有斑点的退化(AMD)并且为经历了ranibizumabmonotherapy因为neovascularAMD在这回顾的study.RESULTSThe一般水准病人年龄被包括的74个病人的74只眼睛的至少2y.METHODSA总数跟随起来是72.1

简介：

简介：

简介：摘要目的探讨Ranibizumab(雷珠单抗)玻璃体腔内注射联合Ex－press青光眼引流钉植入治疗新生血管性青光眼的围手术期护理要点.方法给予１６例新生血管性青光眼患者(１６眼)先行Ranibizumab(雷珠单抗)玻璃体腔内注药术,待虹膜新生血管消退或消失后,行Ex－press青光眼引流钉植入术,充分做好围手术期的各项护理工作.结果１６例患者顺利完成手术.玻璃体注药术后３~７d,１４例患者虹膜新生血管完全消退.术后平均眼压１mo１３．１６±２．８２mmHg,３mo１３．９０±２．５０mmHg,６mo１４．５０±１．４５mmHg,１２mo１５．６２±１．５５mmHg,术后１、３、６、１２mo眼压与术前相比有统计学意义(P＜０．０５).２例视力有提高,１４例患者视力保持原水平.完全成功８例,部分成功５例,手术成功率８１％.结论Ranibizumab玻璃体腔内注射可迅速消退虹膜新生血管,联合Express青光眼引流钉植入术,创伤小,降低眼内出血的风险,是治疗新生血管性青光眼的有效术式,做好围手术期的的护理工作是确保手术疗效的关键.关键词雷珠单抗;Ex－press植入术;新生血管性青光眼;围手术期护理PerioperativenursingcareofRanibizumabcombinedwithEx－pressminiatureglaucomadeviceimplantationforneovascularglaucomaAbstractAbstractobjectiveToevaluatethekeypointsinperioperativenursingcareofRanibizumabcombinedwithEx－pressminiatureglaucomadeviceimplantaＧtionforneovascularglaucoma．METHODS１６eyesof１６patientswithneovascularglaucoma(NVG)weretreatedbyintravitreousinjectionofRanibizumabcomＧbinedwithEx－pressminiatureglaucomadeviceimplantationafteratrophyofirisneovascularization．RESULTSOperationwassuccessfullyperformedin１６paＧtients．Irisneovascularizationwascompletelyregressedduring３－７dafterinjectionin１４eyes．MeanIOPafterEx－presssurgerywas(１３．１６±２．８２),(１３．９０±２．５０),(１４．５０±１．４５),(１５．６２±１．５５)mmHgrespectivelyatmonth１,month３,month６,andmonth１２aftersurgery．TheIOPof８eyeswerelessthan２１mmHgwithoutanydrugsandof５eyeswith１－２kindsofanti－glaucomadrugsafterEx－presssurgery．CONCLUSIONIntravitreousinjectionofRanibizumabcouldsignificantlyreducetheregressionofirisneovascularization．RanibizumabcombinedwithEx－pressminiatureglaucomadeviceimplantationcanstableloweringIOPandhasfewercomplicationsforneurovascularglaucoma．ComprehensivenursingcareduringperioperativeperiodisthekeytoensuretheclinicaleffectoftreatmKeenyt．wordsRanibizumab;Ex－pressimplant;neovascularglaucoma;perioperativenursing中图分类号R４５３文献标识码B文章编号１００８－６３１５(２０１５)１２－０００８－０２０

简介：AIM:Tocomparetheefficacyandsafetyofcombinationofranibizumabwithphotodynamictherapy(PDT)vsranibizumabmonotherapyinthetreatmentofage-relatedmaculardegeneration(AMD).METHODS:TheCochraneCentralRegisterofControlledTrials(CENTRAL)intheCochraneLibrary,Pubmed,andEmbaseweresearched.Therewerenolanguageordatarestrictionsinthesearchfortrials.Onlyrandomizedcontrolledtrials(RCTs)wereincluded.MethodologicalqualityoftheliteratureswasevaluatedaccordingtotheJadadScore.RevMan5.2.6softwarewasusedtodothemeta-analysis.RESULTS:Sevenstudieswereincludedinoursystematicreview,amongwhichfourofthemwereincludedinquantitativeanalysis.Theresultshowsthattheranibizumabmonotherapygrouphadabettermeanbestcorrectedvisualacuity(BCVA)changevsbaselineatmonth12comparedwiththatofthecombinationtreatmentgroup,andthestatisticaldifferencewassignificant(WMD,-2.61;95%CI,-5.08to-0.13;P=0.04).However,aftertheremovalofonestudy,thedifferencebetweenthetwogroupsshowednosignificantdifference(WMD,-2.29;95%CI,-4.81to0.23;P=0.07).Meanwhile,nosignificantcentralretinalthickness(CRT)reductionwasfoundinthecombinationtreatmentgroupandtheranibizumabmonotherapygroupat12monthsfollow-up.Nevertheless,thecombinationgrouptendedtohaveagreaterreductioninCRT(WMD,-4.13μm;95%CI,-25.88to17.63,P=0.71).Theproportionofpatientsgainingmorethan3linesatmonth12intheranibizumabgroupwashigherthaninthecombinationgroupandtherewasasignificantdifference(RR,0.72;95%CI,0.54to0.95;P=0.02).Whereastherewasnosignificantdifferencefortheproportionofpatientsgainingmorethan0lineatmonth12betweenthetwogroups(RR,0.93;95%CI,0.76to1.15;P=0.52).Thegeneraltendencyshowsareductioninranibizumabretreatmentnumberinthecombinationtreatmentgroupcomparedwiththeranibizumabmonotherapygroup.Asmajoradverseevents,thedifferencesinthenumberofeyepain,endophthalmitis,hypertensionandarterialt

简介：

简介：摘要目的研究抗血管内皮生长因子(VEGF)单克隆抗体Ranibizumab玻璃体腔注射治疗渗出型老年性黄斑变性的临床疗效和安全性。方法随机选取我院2012年1月至2015年5月收治的渗出型老年性黄斑变性患者120例（147眼），依据治疗方法将这些患者分为抗VEGF单克隆抗体Ranibizumab玻璃体腔注射组（Ranibizumab组，n=60）和保守治疗组（n=60）两组，对两组患者的血液黏性指标、OA、CRA处的血流动力学指标及治疗指标进行统计分析。结果Ranibizumab组患者的全血粘度、PLT、PDW均显著低于保守治疗组（P<0.05），OA、CRA处的PSV、EDV均显著高于保守治疗组（P<0.05），眼压值、视力均显著高于保守治疗组（P<0.05），黄斑区视网膜厚度显著低于保守治疗组（P<0.05）。结论抗VEGF单克隆抗体Ranibizumab玻璃体腔注射治疗渗出型老年性黄斑变性的临床疗效显著，具有较高的安全性。